Changing How Inflammation is Treated
More than one billion people worldwide suffer from chronic inflammatory diseases. Because of the limitations of treatments that are currently available, many of these people are undertreated or not treated at all. Evelo’s product candidates have the potential to address this unmet need.
Product Candidate
Indication
Preclinical Development
Phase 1
Phase 2
Phase 3
Psoriasis
A dose-ranging Phase 2 trial that evaluated EDP1815 for the treatment of mild to moderate psoriasis. The trial evaluated three doses of EDP1815 versus placebo in approximately 225 individuals, over a 16-week treatment period. Potential registration trials in 2023.
Click here for information on our positive Phase 2 data in psoriasis.
Learn more about our work in Inflammatory DiseasesAtopic dermatitis
A 16 week, double-blind, placebo-controlled trial. Approximately 405 participants were randomized to receive either EDP1815 or placebo (295 to EDP1815: 110 to placebo) and treated for 16 weeks. Participants in Cohorts 1, 2, & 3* were randomized in a 3:1 ratio (225 to EDP1815: 75 to placebo). Participants in Cohort 4 are randomized in a 2:1 ratio (70 to EDP1815: 35 to placebo).
Data from cohort 4 expected in 2Q 2023.
*Data from first 3 cohorts in Phase 2 trial did not meet primary endpoint.
Learn more about our work in Inflammatory DiseasesPsoriasis
Phase 2 psoriasis data anticipated in 2H 2023.
Learn more about our work in Inflammatory DiseasesProduct Candidate
EDP1815
Indication
Psoriasis
Phase
Phase 3
A dose-ranging Phase 2 trial that evaluated EDP1815 for the treatment of mild to moderate psoriasis. The trial evaluated three doses of EDP1815 versus placebo in approximately 225 individuals, over a 16-week treatment period. Potential registration trials in 2023.
Click here for information on our positive Phase 2 data in psoriasis.
Learn more about our work in Inflammatory DiseasesProduct Candidate
EDP1815
Indication
Atopic dermatitis
Phase
Phase 2
A 16 week, double-blind, placebo-controlled trial. Approximately 405 participants were randomized to receive either EDP1815 or placebo (295 to EDP1815: 110 to placebo) and treated for 16 weeks. Participants in Cohorts 1, 2, & 3* were randomized in a 3:1 ratio (225 to EDP1815: 75 to placebo). Participants in Cohort 4 are randomized in a 2:1 ratio (70 to EDP1815: 35 to placebo).
Data from cohort 4 expected in 2Q 2023.
*Data from first 3 cohorts in Phase 2 trial did not meet primary endpoint.
Learn more about our work in Inflammatory DiseasesProduct Candidate
EDP2939
Indication
Psoriasis
Phase
Preclinical Development
Phase 2 psoriasis data anticipated in 2H 2023.
Learn more about our work in Inflammatory DiseasesProduct Candidate
Research
Indication
Inflammation
Phase
Preclinical Development
Partnerships
Let’s work together to spark global change. We seek to partner with pharmaceutical companies, biotechs, universities, and other organizations that are committed to transforming the current healthcare paradigm.
